Express and interpretation on American society of clinical oncology guideline update for Sentinel lymph node biopsy in early-stage breast cancer
WU Ke-jin
Abstract：2014 April, American Society of Clinical Oncology (ASCO) issued new clinical practice guideline on sentinel lymph node biopsy for patients with early-stage breast cancer in Journal of Clinical Oncology (JCO). This guideline update reflects some changes since the 2005 guideline. Based on randomized clinical trials (RCTs), there are three recommendations: (1) Women without sentinel lymph node (SLN) metastases should not accept axillary lymph node dissection (ALND). (2) In most cases, Women with 1-2 metastatic SLNs going to undergo breast-conserving surgery (BCS) with whole-breast radiotherapy should not adopt ALND. (3) Women with SLN metastases planning to receive mastectomy should be provided ALND. Based on cohort studies and/or informal consensus, there are two prime recommendations. (1) Sentinel node biopsy (SNB) may be offered to those women with operable breast cancer and multicentric tumors, with ductal carcinoma in situ (DCIS) planning to undergo mastectomy, who previously got breast and/or axillary surgery or who accepted preoperative/neoadjuvant systemic therapy. (2) SNB should not be offered to those women with large or locally advanced invasive breast cancer (tumor size T3/T4), inflammatory breast cancer, or DCIS will undergo BCS, or are pregnant.
Keywords：early-stage breast cancersentinel node biopsy
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：2( 25-26 )